RecruitingNCT06418165
Vienna Hypothermic Oxygenated Machine Perfusion Study
Vienna Hypothermic Oxygenated Machine Perfusion for Liver Transplantation Study
Sponsor
Medical University of Vienna
Enrollment
500 participants
Start Date
Jan 1, 2018
Study Type
OBSERVATIONAL
Conditions
Summary
In this observational cohort study data on all patients undergoing liver transplantation after hypothermic oxygenated machine perfusion at Medical University of Vienna will be prospectively recorded. Investigation of short- and long-term outcome in this cohort will be conducted.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- patients undergoing liver transplantation with the use of hypothermic oxygenated machine perfusion
- age ≥ 18 years
Exclusion Criteria3
- pregnancy
- partial grafts
- the anatomical integrity of the liver is not preserved in a way that makes the perfusion of the liver possible
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06418165
Related Trials
Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients
NCT056298451 location
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
NCT060775911 location
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
NCT054683592 locations
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT0552895214 locations
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
NCT0679611410 locations